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Abstract After stem cell transplantation, human patients
are prone to life-threatening opportunistic infections with a
plethora of microorganisms. We report a retrospective
study on 116 patients (98 children, 18 adults) who were
transplanted in a pediatric bone marrow transplantation
unit. Blood, urine and stool samples were collected and
monitored for adenovirus (AdV) DNA using polymerase
chain reaction (PCR) and real-time PCR (RT-PCR) on a
regular basis. AdV DNA was detected in 52 (44.8%)
patients, with mortality reaching 19% in this subgroup.
Variables associated with adenovirus infection were trans-
plantations from matched unrelated donors and older age of
the recipient.Anincreasedseasonaloccurrenceofadenoviral
infections was observed in autumn and winter. Analysis of
immune reconstitution showed a higher incidence of AdV
infections during periods of low T-lymphocyte count. This
study also showed a strong interaction between co-infections
of AdV and BK polyomavirus in patients undergoing hema-
topoietic stem cell transplantations.
Introduction
The immune reconstitution period following hematopoietic
stem cell transplantations (HSCT) is accompanied by a
high incidence of viral infection due to profound immu-
nodeﬁciency. Adenoviral infections have been increasingly
recognized as a clinical problem, and their signiﬁcance
needs to be elucidated. There are 52 currently known ser-
otypes of human adenoviruses (AdV) [17, 33], which have
been regarded as life-threatening pathogens after bone
marrow transplantation [7, 9, 16, 31]. They are commonly
detected in stool and pharyngeal swabs of healthy indi-
viduals, causing self-limiting infections of the respiratory
tract, gastrointestinal system, and occasionally, the eye or
urinary tract [1, 3, 7, 10, 12, 16]. In transplant recipients,
AdV may occur as a de novo infection or reactivation of
latent virus after primary infection in childhood [10].
According to different studies, the estimated rate of AdV
infection after HSCT ranges from 3–47% [2, 3, 6, 10, 11,
13, 20–22, 27, 30], with mortality from 10 to 80% [10,
12, 16, 27, 28, 30]. A higher morbidity risk is present in
recipients when the transplant is received from matched
unrelated donors (MUDs) or partially matched family
donors (PMFDs), after ex vivo T cell depletion, at
younger age, in the presence of graft-versus-host disease
(GvHD), after antithymocyte globulin therapy and in
cases of severe lymphopenia at the time of ﬁrst detection
of the virus [1–6, 15, 19, 20, 26, 28, 30]. Lack of efﬁcient
anti-AdV prophylaxis [3, 13, 16, 19, 20, 26] demands
rapid and sensitive detection of human adenoviruses in
clinical practice [26]. In this study, we report the results
of a retrospective trial including 116 stem cell transplant
recipients. Molecular techniques based on polymerase
chain reaction and speciﬁc real-time PCR were used to
detect AdV.
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Deﬁnitions
Adenoviral infection was deﬁned as the presence of AdV
DNA in the clinical sample obtained from whole blood,
plasma, urine or stool, detected by PCR or RT-PCR, irre-
spective of symptoms. In contrast, an active infection was
deﬁned as the presence of AdV DNA in plasma or detec-
tion of an increasing AdV copy number in clinical mate-
rials such as whole blood, urine and stool. Disseminated
disease was deﬁned by AdV detection in at least two dif-
ferent clinical materials at the same time. Local infection
was limited to detection of AdV genome at one body site.
Acute GvHD was graded as grades 0 to IV according to
standard criteria [29]. Mild acute GvHD was deﬁned as
grades I–II, and severe, as III–IV.
Patients and clinical samples
This retrospective study included 116 patients undergoing
HSCT at the local Department of Paediatric Bone Marrow
Transplantation, between 2007 and 2009. All recipients
were tested for AdV infection on a regular basis after
transplantation. The characteristics of the recipients are
shown in Table 1. Due to the high variability of treated
patients, different conditioning regimens were used
(Table 2). Ex vivo T cell depletion of the graft was per-
formed in all haploidentical transplantations (n = 9).
Clinical samples of whole blood, plasma, urine and stool
were collected. Virological surveillance was performed
regularly every 1–2 weeks, starting from the day of trans-
plantation (Day 0) and continued until discharge of the
patient, and once a month afterwards. Parallel to this, a
weekly ﬂow cytometric assessment of lymphocyte (CD3?)
count in peripheral blood samples was performed.
Control virus strains
Six control virus strains of different serotypes, repre-
senting species (A–F), were obtained from American
Type Culture Collection (Manassas, USA). DNA iso-
lated from control virus strains was used for standard
curve preparation. It also served as a target DNA for
positive controls for detection of inhibition in PCR and
RT-PCR.
Preparation and extraction of clinical samples
DNA from whole-blood samples (EDTA) was extracted
immediately after collection. Urine and stool were col-
lected into sterile, disposable containers. Stool samples
were frozen (-20C) immediately after collection and
transported on ice to the laboratory. The samples of plasma
(EDTA) and urine were centrifuged at 3,0009g for 20 min
and 3,0009g for 10 min, respectively, before freezing at
-20C. DNA was extracted from whole blood and plasma
Table 1 Characteristics of the study population
Characteristic No. of patients (%)
Total number of patients (n) 116
Gender
Male 74 (63.8)
Female 42 (36.2)
Age
Children/median (range) 98/8.8 (1–18) years
Adults/ median (range) 18/27.7 (19–44) years
Original disease
Malignance 83 (71.6)
Non-malignant disease 33 (28.5)
ALL 43 (37.1)
AML 24 (20.7)
CML 7 (6.0)
HD and NHL 4 (3.5)
MDS 10 (8.6)
Others 28 (24.1)
Donor type
Matched unrelated donor 76 (65.5)
Relative donor 38 (32.8)
HLA identical sibling donor 27 (23.3)
Haploidentical donor 9 (7.8)
Other related donor 2 (1.7)
Auto 2 (1.7)
Allo 114 (98.3)
Source of progenitor cells
PBPC 89 (76.7)
BM 25 (21.6)
CB 1 (0.9)
CB ? BM 1 (0.9)
Graft manipulation
T cell depletion 9 (7.8)
No T cell depletion 107 (92.2)
Myeloablative conditioning
Yes/no 77 (66.4)/39 (33.6)
ATG
Yes/no 81 (69.8)/35 (30.2)
TBI
Yes/no 32 (27.6)/84 (72.4)
ALL acute lymphoblastic leukaemia, AML acute myelogenous leu-
kaemia, CML chronic myelogenous leukaemia, HD Hodgkin’s lym-
phoma, NHL non-Hodgkin lymphoma, MDS myelodysplastic
syndrome, PBPC peripheral blood progenitor cells, BM bone marrow,
CB cord blood, ATG antithymocyte globulin, TBI total body
irradiation
2008 I. Bil-Lula et al.
123using spin columns from the QIAamp Blood Mini Kit,
from urine, using a QIAamp Viral RNA Mini Kit, and from
stool, using a QIAamp DNA Stool Mini Kit (Qiagen
GmbH, Hilden, Germany) according to the manufacturer’s
instructions. In largely cell-free ﬂuids, RNA carrier was
used. From a starting amount of 200 ll of whole blood or
plasma, 140 ll of urine and 200 mg of stool, 50 llo f
extracted DNA was collected. Six microliters of DNA-
containing extract was used in standard PCR and 7 ll was
used in real-time PCR ampliﬁcation.
Preparation and extraction of control viral DNA
Viral genomic DNA was extracted from 200 ll of viral
lysate, using a QIAamp Blood Mini Kit (Qiagen,
Germany). The control PCR product used for preparation
of the standard curve was puriﬁed by using a QIAquick
PCR Puriﬁcation Kit (Qiagen, Germany).
Standards and calibration curve generation
For quantiﬁcation of virus load, two external standard
curves were applied: one for evaluation of adenoviruses
from AdV species A, C, F and the second for quantiﬁcation
of viruses from AdV species B, D and E. Preparation of the
standard curves was based on serial dilutions of ﬂuoro-
metrically quantiﬁed in-home cloned plasmid standards or
an amplicon quantitative standard prepared using primers
speciﬁc for AdV type 5. Plasmid or amplicon concentration
and purity were determined using a NanoPhotometer
(Implen GmbH, Munich, Germany). The viral copy number
was calculated based on the known molecular weight of the
plasmid and amplicon.
Polymerase chain reaction
The screening examination of all clinical samples was
performed as a singleplex PCR assay in a 20-ll volume
containing 10 ll HotStarTaq Master Mix Kit (QIAagen
GmbH, Germany), 1 ll of forward and reverse primers
(0.5 lM ﬁnal conc.) ADV1 50-GCC GAG AAG GGC GTG
CGC AGG TA-30 and ADV2 50-ATG ACT TTT GAG
GTG GAT CCC ATG GA-30 (TIB MOLBIOL, Poland),
which were described previously [24], 2 ll of distilled
water and 6 ll of target viral nucleic acid. Reference
strains of adenoviruses were used as positive controls in
each run; distilled water instead of template was used as
a negative control. On a basis of ﬂuorometrically quan-
tiﬁed viral DNA, we concluded that it was possible to
reliably detect 7.5 9 10
1 copies of viral DNA per ml of
the sample by classical PCR. Positive samples were
quantiﬁed by real-time PCR (RT-PCR) to determine
virus load.
RT-PCR
Viral copy numbers were quantiﬁed using a real-time PCR
that was developed in our laboratory, based on speciﬁc
primers and probes described elsewhere [7]. Quantitative
ampliﬁcation was performed on Real Time 7500 PCR
Systems (Applied Biosystems, Foster City, USA) in
96-well format by using TaqMan-based chemistry. In brief,
the optimized master mix for the ACF reaction consisted of
13 llo f2 9 TaqMan Universal PCR Master Mix (Applied
Biosystems, Foster City, USA), 1 ll of each primer
(160 nM ﬁnal conc.), except second reverse (320 nM ﬁnal
conc.), 1 ll of each probe (80 nM ﬁnal conc.), 2.6 llI C
Master Mix, 0.52 ll of water, and 7 ll of target DNA
solution in ﬁnal total volume of 32 ll. The reaction for
BDE serotypes consisted of: 12 llo f2 9 TaqMan Uni-
versal PCR Master Mix (Applied Biosystems, Foster City,
USA), 1 ll of 2 primers (160 nM ﬁnal conc.), 1 ll of each
Table 2 Conditioning regimens
Type of
transplant
Conditioning Total no.
(n = 118)
a
Allogeneic Myeloablative
TBI ? VP ± ATG 32
Bu ? Cy ± ATG 22
Bu ? Cy ? Mel ± ATG 9
Bu ? Vp ? Cy ± ATG 7
Bu ? Flu 1
Bu ? Flu ? Mel ? ATG 1
Bu ? Flu ? Cy 1
Bu ? Mel 1
Reduced intensity
Bu ? Flu (GEFA) 4
Flu ? Cy ? ATG 4
Flu ? Mel ? ATG 2
Cy ? ATG 2
Treo ? Cy ± ATG 14
Treo ? Cy ? Mel ? ATG 6
Treo ? Flu ? Mel ? ATG 2
Treo ? Flu ? Cy ? ATG 2
Treo ? Flu 1
Treo ? Cy ? VP ? ATG 1
TBI 8 Gy ? Flu ? Cy ? ATG 1
Syngeneic ATG 1
Autologous BuMel 3
BEAM 1
TBI total body irradiation, VP etoposide, ATG anti-thymocyte glob-
ulin, Bu busulphan, Cy cyclophosphamide, Mel melphalan, Flu ﬂu-
darabine, Treo treosulphan, BEAM, carmustine, etoposide,
cytarabine, melphalan
a Second transplantation in two patients
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123probe (80 nM ﬁnal conc.), 2.4 ll IC MasterMix, 0.6 llo f
water and 7 ll of extracted DNA in a total volume of
26 ll. Quantitative RT-PCR was performed under the
following conditions: 1 cycle at 50C for 2 min for
AmpErase UNG activation, then 95C for 10 min for
denaturation, followed by 55 cycles (95C for 15 s, 60C
for 1 min). TaqMan Exogenous Internal Positive Control
(VIC-probe) from Applied Biosystems (Foster City, USA)
was added during the DNA extraction step (5 ll/200 ll
of lysate) and was coampliﬁed in the multiplex reaction.
To reduce the risk of sample contamination, the
AmpErase system was used. Each run included at least
two no-template controls and three different positive
controls. The lower detection limit was determined by
the analysis of dilution series, created using ﬂuoromet-
rically quantiﬁed DNA of AdV5 (as representative for
ACF reaction) and DNA of AdV21 (as representative of
AdV for BDE reaction). The sensitivity was demon-
strated to be 2.5 (for multiplex reaction detecting viruses
from species A, C, F) and 24 (for multiplex reaction
detecting viruses from species B, D, E) copies of viral
genome/reaction.
Additional methods
Evaluation of blood counts of CD3? T cells was per-
formed on a Cytomics 7500 (Beckman Coulter, USA)
ﬂow-cytometer using anti-CD3?-FITC (BD, USA),
according to manufacturer’s instructions. An Alert Q-PCR
BKV Kit was used for evaluation of BKV infection.
Therapy
In patients with identiﬁed AdV replication and dissemi-
nated infection, therapy with cidofovir (CDV) was insti-
tuted. Cidofovir was administered with adequate hydration
at a dose of 5 mg per kg BW with probenecid 2 h before
and 3 and 8 h after CDV infusion. Therapy was continued
at weekly intervals until clearance of AdV-DNA was
achieved. Patients treated for AdV infection received 2–10
doses (median, four doses) of cidofovir.
Statistical analysis
Statistical analysis was performed using Statistica v.8.0
(StatSoft, Krako ´w, Poland). The chi square test or Fisher’s
exact test was used for a univariate analysis of risk. To
evaluate multiple risk factors for infection, a logistic
regression model was used. An incidence of AdV-related
death among the AdV-infected patients was analyzed by
the Kaplan–Meier product-limit method and compared
with log-rank and Cox–Mantel tests. The immunological
status, based on the CD3? cell count, was used to cate-
gorize patients into four groups (\500,\1,000,\2,000 and
\6,500/ll), and its impact on adenoviral infection was
determined using correspondence analysis and the Coch-
ran–Cox test. Mean copy numbers of AdV in MUD,
MMREL and IDSIB recipients were compared using
ANOVA. The AdV dependence of concomitant infections
was evaluated by Mann–Whitney test.
Results
Incidence of adenovirus infection and risk factors
Adenoviral infection was detected in 52 (44.8%) of 116
transplant recipients. No infections occurred in autograft
recipients. The median age of AdV-infected patients at the
time of HSCT was 9.5 years (range 1.0–44.0), with 36
male and 16 female patients. Morbidity was uniformly
distributed among different periods after transplantation:
20% (0–3 weeks after HSCT), 21% (3–6 weeks), 17%
(6–9 weeks), 18% (9–15 weeks) and 24% ([15 weeks)
(p[0.05). Of 52 infected patients, 10 died (8 MUD and 2
MSD) at a mean time of 98.4 days (range 11–245) after
transplantation. GvHD was diagnosed in 7 of 10 (70%)
patients who succumbed after HSCT: 4 GvHD I–II and 3
GvHD IV. GvHD was observed in 24 of 42 patients who
survived, but 18/24 (75%) of them developed GvHD I–II,
and 6/24 (25%) developed GvHD III–IV (p = 0.44). There
was only one patient with GvHD IV in the group of infected
patients who survived (p = 0.003). The probability of
Fig. 1 a Estimation of survival
of patients with and without
adenoviral infection after
HSCT. The probability of
survival was similar for infected
and uninfected recipients
(p = 0.26), b the probability of
survival after HSCT in relation
to age (p = 0.006), log-rank test
2010 I. Bil-Lula et al.
123survival was 0.76 in the case of AdV-infected patients,
whereas the probability was 0.64 in the case of AdV-free
patients, but this difference was not signiﬁcant (p = 0.26)
(Fig. 1a). Analyzing factors affecting survival of the AdV
cohort, the patient’s age was signiﬁcant (p = 0.006). The
probability of survival for 200 days after HSCT decreased
with older age, 1–7 years (0.85), 8–14 years (0.76),
15–21 years (0.63), and reached a minimum in the age
group 22–28 (0.46) (Fig. 1b).
The most common sites of AdV-DNA isolation were
stool 12/24 (50%) and urine 56/116 (48.3%), followed by
whole blood 30/116 (25.9%) and plasma 22/116 (18.9 %).
The median time from transplantation to the ﬁrst AdV-
positive result from urine was 17 days after HSCT (range
7–59) and 38 days in whole blood (range 7–183). In 3
patients, we were able to detect AdV-DNA as early as on
Day 7 in urine or whole blood samples. This might indicate
the necessity for AdV monitoring to start by at least Day 7
after transplantation. Blood positivity for AdV-DNA pre-
ceded plasma positivity on average by 2 days. Nineteen out
of 52 patients developed disseminated infection: plasma
and urine (28.8%), urine and stool (7.7%). The viral load in
cases of disseminated disease did not exceed 10
4 copies/ml
or gram of the sample (Fig. 2). Medium concentrations
were as follows: 4.7 9 10
3 copies/ml in urine, 3.4 9 10
4
copies/ml in plasma, and 2.3 9 10
3 copies/g in stool.
In 33/52 (63.5%) infected patients, local AdV infection
was found in urine 29/52 (55.8%), plasma 1/52 (1.9%) or
stool 3/52 (5.8%). Median concentration: urine, 7.4 9 10
2
copies/ml;plasma,8.3 9 10
3 copies/ml;andstool,5.6 9 10
2
copies/ml.
Among patients with local infection, 5 of 33 (15.2%)
died. Disseminated disease, surprisingly, was not associ-
ated with higher mortality (p = 0.63) in comparison to
patients with local infection. Mortality among patients with
disseminated disease was 5/19 (26.3%). Adenoviruses were
more frequently isolated from the blood and urinary tract of
recipients of grafts from unrelated donors (MUD) (19%)
than mismatched related (MMREL) (8%) or sibling (ID-
SIB) (10%) donors (p = 0.004). The mean copy numbers
are listed in Table 3.
On univariate analysis, the AdV infection rate was
correlated with older age of the patient (p = 0.005), and
among children, the highest morbidity was observed
between 7 to 12 years. T cell-depleted transplantations made
up only 7.8% of all transplantations (9/116). According to
the results from our study group, depletion of T cells from
the graft material did not make patients more prone to
adenoviral infections. Adenoviral DNA was found in blood
(27/107), plasma (20/107) and urine (48/107) from patients
undergoing non-T-depleted transplantations and in blood
(3/9), plasma (2/9) and urine (2/9) of T cell depleted
transplantations (p[0.05). The use of anti-thymocyte
globulin (ATG) and total body irradiation (TBI) in
Fig. 2 Viral load in blood and urine of two recipients. HSCT, hematopoietic stem cell transplantation
Table 3 Mean copy number of AdV in clinical samples
Recipients of graft from Mean copy number (SD) (copies/ml, copies/g)
Whole blood Plasma Urine Stool
MUD 1.5 9 10
3 (83.0) 1.1 9 10
2 (11.0) 2.3 9 10
3 (4,969.8) 8.4 9 10
1 (40.1)
MMREL 1.7 9 10
3 (3,835.5) 8.3 9 10
3 (47,789.8) 2.7 9 10
3 (13,052.9) 1.5 9 10
4 (47,800.7)
IDSIB 5.7 9 10
2 (907.3) 1.0 9 10
3 (1,939.6) 2.4 9 10
3 (2,994.6) 9.4 9 10
4 (13,199.5)
There was no difference in mean copy number of AdV in blood, plasma, urine and stool samples from patients who received grafts from MUD,
MMREL and IDSIB donors. ANOVA, p[0.05
MUD matched unrelated donors, MMREL mismatched related donors, IDSIB identical sibling donors, SD standard deviation
Adenovirus infections in stem cell transplant recipients 2011
123conditioningregimenshadnoinﬂuenceonvirusappearance,
39/81 versus 15/35 and 16/32 versus 38/84, respectively,
p[0.05. This conﬁrms the suggestion that prevention of
graft rejection by anti-thymocyte globulin and TBI does not
conduce adenoviral infections as much as was thought pre-
viously. Seasonal ﬂuctuations of adenoviral infection were
observed. The incidence of AdV infections in each season
wasasfollows:spring11/45(24.4%),summer9/19(47.4%),
autumn 13/25 (52%) and winter 19/27 (70.4%) (p = 0.001)
(Fig. 3).
No signiﬁcant differences in AdV morbidity between
peripheral blood (41/89) and bone marrow recipients (13/
25) (p[0.05) were observed. The gender of the recipient
or donor was not associated with greater incidence of AdV
infection (p[0.05), female 43 versus male 48%. The
incidence rates of AdV infections were similar according to
primary disease; patients with malignant and non-malig-
nant disorders had virtually identical morbidity (46 vs.
47%, p = 0.88).
Adenovirus infection and immune reconstruction
Analysis by median comparison showed that the median
number of CD3? cells in AdV-infected patients (median
490/ll, range 0–3,309/ll) was lower than among AdV-free
recipients (median 665/ll, range 0–6,476/ll), p = 0.04.
Correspondence analysis conﬁrmed that AdV-free samples
correlated with higher CD3? cells counts (1,000–6,400/ll)
(Fig. 4).
BK polyomavirus co-infections
Seven hundred ﬁfty-two plasma and 705 urine samples
were tested for concomitant infections with BK polyoma-
virus. Some patients presented co-infections after infection
with one viral agent; therefore, examination of clinical
materials was the basis of segregation. DNA of both AdV
and BKV was detected in 39 plasma and 111 urine sam-
ples. One hundred seventeen plasma samples and 276 urine
samples were positive for BK polyomavirus only, whereas
43 plasma and 58 urine samples contained AdV-DNA only.
Co-occurrence of AdV and BKV both in plasma
(p\0.001) and in urine (p = 0.001) was statistically
signiﬁcant. Analysis using the Chi square test suggested
that the presence of one virus was conductive to the
occurrence of a concomitant virus. Examination of multi-
ple risk factors (logistic regression) conﬁrmed that BKV
infection and transplantation from MUD increase the risk
of AdV infection (p\0.001 and p = 0.013, respectively).
Correspondence analysis showed that, in most cases, both
AdV and BKV are present together or both are absent.
Wald–Wolfowitz and Mann–Whitney tests were used to
compare mean viral loads of both viruses in co-infections.
Viral copy numbers were different in plasma (p\0.001)
and urine (p = 0.02). The AdV load was higher in plasma
(mean 5.8 9 10
3 copies/ml) and urine (mean 1.1 9 10
2
copies/ml) in co-infected samples than in the samples
without BKV: plasma (mean 9.2 9 10
1 copies/ml), urine
(mean 6.6 9 10
1 copies/ml). This conﬁrms that infection
with one virus type facilitates replication of the other virus.
We also conﬁrmed that the total number of CD3? cells in
peripheral blood in patients with AdV/BKV co-infections
in plasma was signiﬁcantly lower (352 ± 747 cells/ll) than
in those with only AdV infection (434 ± 491 cells/ll)
(p = 0.037). We could not conﬁrm this observation for co-
infections in urine. Multivariate analysis with logistic
regression revealed that BKV infection and unrelated graft
recipients played a role in the development of AdV
infection (p\0.001).
Fig. 3 Seasonal incidence of adenovirus infections of hematopoietic
stem cell transplant recipients. Winter and autumn were the most
frequent seasons for infections (p = 0.007)
Fig. 4 Correlation between CD3? cells (ll) and AdV viral load
(copies/ll). CD3? cell count and AdV copy number were determined
on the same day of the post-transplantation period. Viral load refers to
blood, plasma, urine and stool samples
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Our results show that adenoviral infections are very com-
mon in recipients undergoing HSCT. Previous studies
indicated a moderate frequency of adenovirus infections in
allogeneic SCT [3, 6, 22] associated with signiﬁcant mor-
tality [10]. This study demonstrated a high proportion
(44.8%) of AdV-infected recipients, with a mortality risk
of 19.2% (10/52). Our data, like those published by Walls
et al. [31], Ison [16] and Myers et al. [25] show a higher
incidence of adenoviral infection than data reported before
the year 2003 by others [2, 3, 6, 10, 22, 28]. Therefore, we
believe that the greater incidence of AdV infections in our
study group might be a result of more sensitive methods
used for AdV detection. We also need to mention the high
proportion of AdV-positive stool samples and the low
threshold for positivity in our research, which might also
have an inﬂuence on the greater proportion of positive
results. Our group consisted predominantly of MUD
transplantation recipients (65.5%), who are more suscep-
tible to AdV infections [30]. Moreover, due to application
of molecular methods, we achieved very high sensitivity in
the analysis of large-volume body ﬂuid samples.
It has been suggested that there is a higher incidence of
infection in children compared to adults [1, 2, 21, 22, 30].
Data reported by Chakrabarti et al. [6] pointed to a lack of
dependence between age and infection. In our cohort, older
age was associated with a greater incidence of AdV
infection (p\0.05). The proportion of MUD HSCT in
children (62/98, 63.2%) was similar to that of the adult
group (14/18, 77.7%). The highest incidence in the medium
age group of children may be the result of possible
enhanced replication of latent virus, because over 80% of
children are infected by adenoviruses by age 6 [10]. Per-
sistent infections are predominantly caused by AdV from
species C. The AdV serotypes from species C are also the
most common infections in childhood.
Examined risk factors for adenoviral infections included
the recipient’s sex and underlying disease. The role of such
factors was not observed in our study, in contrast to other
publications [5, 6, 30]. Previous studies also usually doc-
umented the onset of adenovirus infection during the ﬁrst
100 days after transplantation [6, 20, 28]. Our study has
shown no difference between the early and late period after
HSCT.
Interestingly, we detected an increased seasonal inci-
dence of adenoviral infections in winter and autumn. This
is consistent with AdV morbidity in healthy individuals,
suggesting the importance of airborne and droplet trans-
mission of the virus. Because of this, more attention should
be paid to limiting visitor access to the patients.
In 36.5% of AdV patients, disseminated infection was
found, but the prognosis for these patients was not worse
than for those with localized disease. The presence of
disseminated disease was not associated with higher mor-
tality, even with a high viral load in plasma. Similar
observations were made by other investigators, which may
be attributed to rapid institution of cidofovir therapy in
patients with identiﬁed dissemination of infection [6, 14,
28, 32].
The most common site of AdV isolation was stool,
followed by urine, then whole blood and plasma. This is
similar to the results of Baldwin et al. [2] and consistent
with healthy patients developing enteritis and upper
respiratory tract infections [8]. We investigated testing of
whole blood samples. Excluding the cases of latency in
lymphocytes of whole blood (deﬁned as AdV-DNA pres-
ence only in whole-blood samples without an increase of
viral load in whole blood and without the presence of virus
in plasma or other tested materials at the same time), we
noticed that AdV DNA was detected in blood at least
2 days before an active infection. Hence, monitoring of
peripheral blood samples may have predictive value in
surveillance of infection development.
We showed that the use of anti-thymocyte globulin and
total body irradiation in the conditioning regimen did not
increase the risk of AdV infection in stem cell transplan-
tation recipients. The majority of the patients tested
received stem cells from peripheral blood (89/116), and
there was no difference in AdV morbidity between
peripheral blood progenitor cell (PBPC) and bone marrow
(BM) recipients. Our study showed that recipients of
unmanipulated graft material are not more likely to develop
AdV infections, so a larger number of donor lymphocytes
is probably not associated with greater transmission of
latent AdV. The role of donor lymphocytes in the trans-
mission of viruses from donor to recipient still needs to be
elucidated.
Graft recipients are generally more susceptible to
infections during post transplant recovery [25].
In concordance with some studies [16, 27], in our study,
3 of 7 patients who died after transplantation developed
acute grade IV GvHD (p = 0.003). This may suggest a
strong correlation between GvHD and the patient’s sur-
vival. GvHD requires immunosuppressive therapy, which
lowers the number of lymphocytes and hampers the
immunity of the recipient, thus enabling adenoviral infec-
tions. A low lymphocyte count due to immunosuppressive
treatment or delayed T cell reconstitution was an important
predictor for detection of adenoviral infections in our
study, which is consistent with earlier observations [5, 6].
An inadequate humoral response due to B lymphocyte
impairment can also contribute to AdV infection suscep-
tibility [11].
Multiple plasma and urine samples were positive for
both AdV and BKV. The CD3? cell number in AdV/BKV
Adenovirus infections in stem cell transplant recipients 2013
123co-infected patients was also lower than in those with
isolated AdV infection. The occurrence of BK polyoma-
virus might intensify replication of AdV, because the AdV
load was signiﬁcantly higher in co-infection than in sam-
ples with AdV infection alone. Therefore, greater immu-
nodeﬁciency may promote infections with more than one
viral agent, and a low lymphocyte count in peripheral
blood due to delayed immune recovery may facilitate the
replication of AdV. This mechanism may not be sufﬁcient
to explain viral co-infections in all transplant recipients,
because we identiﬁed cases that were asymptomatic and
diagnosed in a state of relative immunocompetence. From
a molecular point of view, the presence of co-infections
may also be a result of interactions between cohabitating
viruses due to transactivation of gene expression of other
viruses. There are known examples of viral regulatory
proteins that transactivate promoter sequences of heterol-
ogous viruses. Polyomavirus T antigen increases expression
fromtheadenovirusE2promoter,andthistransactivationisas
efﬁcient as the homologous viral protein ElA [23]. Kristof-
fersenetal.[18]reportedthatBKlargeTantigenenhancedthe
expression of human CMV IE genes through heterologous
transcriptionaltransactivationoftheCMVmajorIEpromoter
in A549 cells. On this basis, it may be concluded that aden-
oviral transcription factors regulating speciﬁc target promot-
ers can be induced by different viral regulatory proteins, like
those of polyomaviruses. The reason for the higher AdV load
inurinesampleswithconcomitantBKpolyomavirusinfection
is still unclear and needs to be determined in a broader
examination. It is a noteworthy observation that patients can
be afﬂicted by multiple viral infections, which might origi-
nally result from the prevalence of common risk factors,
althoughoneneedstoconsiderthereciprocalenhancementof
viral infections.
Our research conﬁrms that adenovirus viremia is not
always associated with fatal outcome. This clinical effect
might be explained by the high efﬁcacy of aggressive
cidofovir therapy in patients with disseminated disease,
even without symptomatic disease. The crucial factor in
AdV therapy appears to be prompt detection and early
initiation of appropriate anti-viral therapy in high-risk
patients.
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